The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.

For a limited time, patients with a prescription can get a steep discount on the popular medications, as long as they’re paying out of pocket.

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) announced price cuts

The cash price for popular weight-loss medication Wegovy is dropping by 30% in U.S. on Monday, according to Novo Nordisk.

The Danish drugmaker said it's cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly.

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med | The company filed its bid for a 7.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain challenging for patients without insurance.

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month. Then the monthly cost will rise to $349.

Novo Nordisk is filing its supplemental new drug application (sNDA) for Wegovy 7.2 mg on the back of the phase 3b STEP UP obesity trial in more than 1,400 patients, with an average starting weight of 249 pounds (113 kg), which compared it to the standard 2.6 mg weekly dose or a matched placebo over 72 weeks.